NCT05683184

OMAR Opioid Use Disorder

Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.

Detailed description

The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand \[11C\] OMAR, in healthy individuals and individuals diagnosed with opioid use disorder. Research participants may complete screening, MRI, PET scan and follow up visits.

Conditions

• Healthy Control
• Opioid Use Disorder

Interventions

Type	Name	Description
DRUG	[11C]OMAR	For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.

Timeline

• Start date: 2023-03-10
• Primary completion: 2026-12-15
• Completion: 2026-12-15
• First posted: 2023-01-13
• Last updated: 2025-12-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study